Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the hepatic uptake of Primovist® after intravenous
administration of 25 µmol/kg body weight in 56 healthy volunteers and in 60 patients with a
liver disease in dependence on the OATP1B1- and OATP1B3-genotype.